Cymbalta, which was first used to treat major depressive disorder in 2004, is also approved for the treatment of diabetic peripheral neuropathy, generalized anxiety disorder and maintenance treatment of major depression and fibromyalgia.
More than 29,000 patients have used Cymbalta in clinical trials, and more than 600 patients were studied in the clinical trials involving osteoarthritis and chronic low back pain. The safety evaluation for Cymbalta included review of data from the clinical trials as well as post-marketing data from the previously approved patient populations.
The FDA assessed the efficacy of Cymbalta in chronic low back pain and osteoarthritis in four double-blind, placebo-controlled, randomized clinical trials. At the end of the study period, patients taking Cymbalta had a significantly greater pain reduction compared with placebo.
Read the FDA news release about FDA-approved Cymbalta.
Read other coverage about pain management:
– Community Health Center Grant to Support Pain Management Study
– Transdermal Prescription Pain Products to Reach $9.2B by 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.